MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
International Journal of Gynecological Cancer
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

914 results · 1 filter active ·
Results by year
20002025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
914 works in the cohort · of 4,299,418page 8 of 19

Labels cover 3 of 914 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 914 of 914 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
How long is long enough? An international survey exploring practice variations on the recommended duration of maintenance therapy with PARP inhibitors in patients with platinum sensitive recurrent ovarian cancer and long-term outcomes
Lucy Haggstrom, Yeh Chen Lee, Clare L. Scott, Philipp Harter, Linn Woelber, Jonathan A. Ledermann +18 more
2024· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
4
citations
affno abstractunlabeled
Survival Benefit of Adjuvant Radiotherapy
Aalok Kumar, Nhu D. Le, C. Blake Gilks, Jennifer L. Santos, Frances Wong, Kenneth D. Swenerton +3 more
2017· article· fr· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
4
citations
affno abstractunlabeled
Placenta increta mimicking placental site trophoblastic tumor
Mitchell Clark, Naïri Tchrakian, Blaise Clarke, Ur Metser, Geneviève Bouchard‐Fortier
2021· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
affno abstractunlabeled
#1120 Durvalumab with paclitaxel/carboplatin + bevacizumab then maintenance durvalumab, bevacizumab + olaparib in patients with newly diagnosed advanced ovarian cancer without a tumour BRCA1/2 mutation: results from the DUO-O/ENGOT-Ov46/AGO-OVAR 23/GOG-3025 trial
Christian Marth, Tjoung‐Won Park‐Simon, Carol Aghajanian, Alexander Reuß, Shin Nishio, Myong Cheol Lim +14 more
2023· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
affaboutno abstractunlabeled
Low-Risk Gestational Trophoblastic Neoplasia in Manitoba
Vanessa Carlson, Leslea Walters, Pascal Lambert, Erin Dean, Robert Lotocki, Alon D. Altman
2018· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
affno abstractunlabeled
#1015 Mirvetuximab soravtansine demonstrates longer overall survival and progression-free survival by prior lines of therapy vs chemotherapy in platinum-resistant ovarian cancer and high folate receptor alpha expression in the MIRASOL trial
Toon Van Gorp, Renaud Sabatier, Gottfried E. Konecny, J. B. Gordon, Sandro Pignata, Nicoletta Colombo +14 more
2023· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
3
citations
affno abstractunlabeled
Coping With Cancer
Sarah N. Smith, Donna R. Chizen, Anita Agrawal
2014· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
Intraperitoneal Chemotherapy
Walter H. Gotlieb
2010· review· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
Cost-Efficiency of Robotic Surgery
Al Covens, Christhardt Köhler, Joo‐Hyun Nam, R. Wendel Naumann, Andreas Obermair, Denis Querleu
2016· letter· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
Maintenance olaparib after platinum-based chemotherapy in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: efficacy by the timing of surgery and residual tumour status following upfront or interval cytoreductive surgery in the Phase III SOLO1 trial
Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, B-G. Kim, Ana Oaknin, Michael Friedländer +15 more
2019· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
Management of Wolffian adnexal tumors
Soyoun Rachel Kim, Fernando Martínez Heredia, Sara Pakbaz, Ur Metser, Stéphane Laframboise
2021· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
2
citations
affno abstractunlabeled
TP016/#1442 Keynote-C93/GOG-3064/ENGOT-EN15: phase 3, randomized, open-label study of first-line pembrolizumab versus platinum-doublet chemotherapy in mismatch repair deficient advanced or recurrent endometrial carcinoma
Brian M. Slomovitz, David Cibula, Murat Gültekin, Mansoor Raza Mirza, Beata Maćkowiak-Matejczyk, Alexandra A. Taylor +14 more
2022· article· en· International Journal of Gynecological Cancer· Medicine
machine prediction:candidate · noneconsensus · none
2
citations

How this was built: Screen · Findings · About